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In Table 3 on page 358 under the heading
Dose modifications for Empagliflozin the
sentence ‘‘Contraindicated in patients with
creatinine clearance \45 ml/min’’ should read
‘‘Stopped in patients with creatinine clearance
\45 ml/min’’.
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